US FDA approves expanded use of Amgen's rare disease drug
The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...
Pharma stocks survive market rout on tariff exemption, but uncertainty continues
By Maggie Fick and Kashish Tandon LONDON/BENGALURU (Reuters) -Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from reciprocal ...
Managed Healthcare Executive7d
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, ...
FDA Approves Second Indication for Amgen's Immune System Treatment Uplizna
Amgen said the Food and Drug Administration approved Uplizna for Immunoglobulin G4-related disease, the second approved indication. The biotechnology company said Thursday the FDA granted breakthrough ...
BioSpace4d
FDA Action Alert: Amgen, Aldeyra and Argenx
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.